387 results about "Ocular disease" patented technology

The invention discloses an optic disk atrophy arc image segmentation method based on full supervision, and particularly relates to the technical field of medical equipment, and the method comprises the following steps: S1, multi-scale feature extraction, S2, local-global feature enhancement, S3, adaptive feature fusion, S4, gradient flow optimization, S5, mixing of a loss function, and S6, data enhancement and generalization optimization. According to the method, the long-range dependence of the optic disk and the atrophic arc is globally modeled through the PVTv2 encoder, the detail segmentation precision of the optic disk atrophic arc at the blood vessel crossing and fuzzy boundary is remarkably improved in combination with the multi-scale attention and dilated convolution of the feature enhancement module, cross-level feature fusion is realized with linear complexity based on the Mama decoder, and the accuracy of feature fusion is improved. Efficiency and structure coherence are considered; the weight is balanced by the mixed loss function, and early lesion missing detection is reduced; a data enhancement and residual module enhances the generalization ability of the model, and a high-precision and efficient quantitative analysis tool is integrally provided for early screening of blind eye diseases such as pathological myopia and glaucoma.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention discloses an ophthalmology AI intelligent ward control system and method based on voice interaction. The system comprises an anti-noise voice acquisition unit, a multi-modal identity verification unit, a specialized semantic analysis unit, a medical rule engine unit, a safety protection unit, a multi-modal feedback unit and a dynamic optimization unit. Medical equipment noise is filtered out through a microphone array and an adaptive beam forming technology, and an instruction is analyzed in combination with a dialect recognition engine; executing triple identity verification, and performing forced superposition authentication on the cognitive impairment patient; calling an ophthalmology knowledge base to identify the risk keyword and generate a structured instruction; dynamically regulating and controlling the environment according to the eye disease type, and intercepting violation settlement according to a medical insurance rule; precise equipment voice control is forbidden, and when an emergency keyword is triggered, an OCT image is pushed preferentially and is directly connected with a physician; a big-character highlight interface and tactile pulse feedback are provided for the visually impaired patient, and data are synchronized to the HIS system in real time; and the dynamic optimization unit continuously updates the knowledge base and the medical insurance model. According to the invention, the instruction identification precision, the medical safety and the service suitability of the ophthalmology ward are obviously improved.

Compositions for treating ocular disease are disclosed herein. In some embodiments, the composition comprises a dynamic hydrogel comprising a polymer and a plurality of nanoparticles, wherein the polymer is non-covalently crosslinked with the plurality of nanoparticles. The dynamic hydrogel can also comprise an ocular therapeutic encapsulated by the dynamic hydrogel.

A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.

In certain embodiments, the present invention relates to dendrimer-like hyperbranched macromolecules for use in several uses, such as medical or biopharmaceutical applications, or non-medical or industrial applications, such as antibody purification, cosmetic applications, catalytic applications, applications in electronics, agriculture, food, filtration, and other applications. In an embodiment, the present invention relates to a hyperbranched macromolecule for drug delivery comprising a polyethylene glycol (PEG) unit and at least one active agent conjugated to the hyperbranched macromolecule. In addition, methods for synthesizing, purifying and characterizing such hyperbranched macromolecules and methods of treating medical conditions, such as treating ocular diseases, are provided.

The invention discloses a thyroid-related eye disease auxiliary verification method based on SPECT / CT and federal learning. The thyroid-related eye disease auxiliary verification method comprises the steps that A, image data standardization and orbit area extraction are carried out; b, extracting a preliminary segmentation mask of each rectus in the CT image; c, fusing the structure prior mask, and obtaining an extraocular muscle fine segmentation mask through multi-mode collaborative segmentation; d, utilizing extraocular muscle fine segmentation masks, SPECT and CT images, fusing segmentation prior and multi-modal features to perform deep discrimination, performing automatic prediction of thyroid-related eye disease activity staging, and outputting a prediction probability; and E, based on a dynamic model combination strategy of style similarity and uncertainty quantization, obtaining a dynamic combination model of segmentation and classification adapted to new domain feature distribution, and predicting TAO activity. According to the method, accurate segmentation of extraocular muscle structures and accurate prediction of TAO activity in an invisible data center can be realized, auxiliary verification data support is provided for diagnosis of thyroid-related eye diseases, and the diagnosis accuracy is improved.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases / disorders and rheumatic diseases / disorders.

The invention provides an image-based eye lesion grading analysis method and device, a medium, a program product and a terminal, and the method comprises the steps: obtaining one or more eye lesion images, inputting the one or more eye lesion images to a pre-trained first model, and generating a corresponding eye feature vector; for a single image, calculating the similarity between the feature vector and each eye disease category, and outputting a prediction category with the highest similarity; and for a plurality of images, respectively calculating the similarity between the feature vectors and each category, and realizing adaptive weighted integration by using the second model to obtain a final prediction category. Sub-model subdivision and risk level layering are carried out according to prediction categories, and a structured risk layering report is output. The problem that in the prior art, the diagnostic value of multi-image information in complex cases is difficult to effectively evaluate is solved, the accuracy of ultrasound in serious vitreous lesion and intraocular tumor recognition is remarkably improved through a self-adaptive weighted integration mechanism, high-risk patient screening and clinical decision making are supported, and the application scene of ultrasound in ophthalmic diagnosis is expanded.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

The invention discloses a fundus image diagnosis method based on a fusion attention mechanism, and the method comprises the following steps: obtaining a to-be-processed fundus image, and carrying out the normalization processing of the fundus image; performing optic disc segmentation on the fundus image through an encoder-decoder network Attention U-Net embedded with an attention mechanism, and generating a segmentation mask; inputting the segmented mask and the original fundus image into a dynamic weighted feature fusion module to generate a fused image; performing feature extraction on the fused image through a ResNet classification network, and outputting an eye disease classification result; wherein the segmentation and classification tasks are subjected to end-to-end training through joint optimization of a loss function.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly anterior and posterior segment ocular diseases and physical disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases and physical disorders, as well as methods of manufacturing such compositions. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including anterior and posterior segment ocular diseases or disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases or disorders.

Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

The invention discloses a continuous optical zoom slit-lamp microscope system and an inspection method and application thereof, and belongs to the technical field of ophthalmology medical equipment. The system is composed of a continuous zooming module, a light source module, a data processing module, a 3D imaging module and an AI identification module. The inspection method comprises the steps of equipment initialization and head position fixation of an inspected person, AI low-magnification (5 *) preliminary screening, adaptive lens high-magnification (40 *) fine observation, dynamic light source adjustment, three-dimensional data acquisition and cloud intelligent diagnosis. The method is applied to examination and intelligent diagnosis of eye diseases such as cataract. The problems that a traditional slit-lamp microscope is discontinuous in zooming, inconvenient to operate, lack of intelligent diagnosis and free of 3D stereoscopic display are solved, and the objective of the invention is to realize simple and convenient equipment operation, continuous examination process, intelligent diagnosis and stereoscopic display, facilitate collective teaching, significantly improve the diagnosis efficiency and accuracy of eye diseases such as cataract and the like, and improve the diagnosis efficiency and accuracy of eye diseases such as cataract and the like. And DICOM standard data cloud sharing and remote consultation are supported.

The present invention relates to a protein tyrosine kinase inhibitor for the treatment of protein tyrosine kinase-mediated proliferative diseases or symptoms, for example ocular diseases including pathological neovascularization, retinal ischemia, retinal edema, and diabetic retinopathy, as well as malignant tumors. More particularly, the present invention relates to a compound with protein tyrosine kinase inhibitory activity and / or improved solubility and ocular bioavailability, and its uses in the treatment of ocular diseases and malignant tumors.

The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.

The use of an opioid molecule, the levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3] dioxolo [4,5-glisoquinolin-5-yl]-3H-2-benzofuran-1-one, capable of CFTR modulation and of suppressing the degranulation of basophils and mast cells, for the treatment of dry eye and eyes suffering from allergies.

The present invention provides: a novel azabicyclo derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating autotaxin-related diseases, comprising the same as an active ingredient. The azabicyclo derivative compound according to the present invention exhibits excellent inhibitory activity against autotaxin, and thus can be used for treating and preventing diseases associated with autotaxin inhibition. The compounds can be used for treating diseases such as fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancers and cancer metastases, ocular diseases, cholestatic and other forms of chronic pruritus, and acute or chronic organ transplant rejection.

A composition includes an extract portion extracted from a plant selected from rosewood, myrtle, rosemary, and combinations thereof, and a carrier liquid portion. Uses of the compositions for ameliorating one or more ocular diseases and conditions are provided. Eye drop formulations containing the composition are provided.

Provided herein are screening methods and animal models relevant to ocular diseases such as age-related macular degeneration (AMD), e.g., for use in identifying candidate therapeutics for treating or preventing ocular diseases such as AMD. Also provided herein are compounds / compositions useful for killing or inhibiting the growth of microorganisms such as Bacillus megaterium. Further provided herein are methods of using the compounds / compositions to treat infections with microorganisms such as Bacillus megaterium, as well as to treat or prevent diseases or conditions associated with such infections, such as AMD.

The invention relates to the technical field of biological medicine, in particular to a medicine for improving thyroid-related eye diseases and application of the medicine. The single-chain antibody provided by the invention has small molecular weight and good physiological activity, and can effectively inhibit the activity and function of IGF1R mediated by IGF1, thereby inhibiting cell proliferation. According to the medicine prepared from the recombinant adeno-associated virus, the treatment cost can be remarkably reduced, side effects caused by repeated injection of antibody medicines are avoided, the safety is very high, and a new clinical treatment method and strategy are provided for inhibiting pathological phenotypes of thyroid-associated ophthalmopathy.

The present invention concerns an ophthalmic composition comprising:hyaluronic acid, or one of its salts, advantageously of a molecular weight comprised between 100 and 800 kDa;an oligosaccharide, advantageously a diholoside, more advantageously trehalose; andresveratrol;and its use for treating ocular diseases such as DED.

An implant device for an eye disease to be inserted into an eyeball may include: a tube having one end to be inserted into an anterior chamber of the eyeball, the tube comprising a hollow portion through which aqueous humor is drained; and a ripcord inserted into the hollow portion of the tube to control an amount of aqueous humor drainage through the tube. In the implant device, an inner diameter of the tube and a diameter of the ripcord are determined so that pressure formed in the anterior chamber of the eyeball when the tube is inserted into the anterior chamber of the eyeball is within a preset pressure range. The pressure formed in an anterior chamber to an optimal range through an appropriate combination of the tube and the ripcord inserted into the tube.

In one aspect, the present application provides azabicyclo and diazepine derivatives useful as muscarinic receptor modulators. In another aspect, the present application provides pharmaceutical compositions for the treatment of ocular diseases, the compositions comprising at least one muscarinic receptor modulator. Formulas (I) and (II):

Provided herein are methods and compositions for improving the visual function of the eye of a subject having an ocular condition. Provided herein are methods of improving visual function of the eye of a subject suffering from an ocular disease or condition, the method comprising: (a) administering a first composition comprising a Fas inhibitor; and (b) administering a second composition comprising a Fas inhibitor, wherein the second composition is administered for about 10 weeks or more after the first composition is administered.